Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors

Journal of Gene Medicine

Volumn 12, Issue 7, 2010, Pages 613-623

  Maldonado, Arturo R ^a,b   Klanke, Chuck ^a   Jeßgga, Anil G ^a,b   Aronow, Bruce J ^a,b   Mahller, Yonatan Y ^a,b   Cripe, Timothy P ^a,b   Crombleholme, Timothy M ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Herpes simplex virus; MDK; Midkine; MPNST; Oncolytic virus

Indexed keywords

BETA INTERFERON; ONCOLYTIC HERPES VIRUS; VIRUS FUSION PROTEIN; LUCIFERASE; MDK PROTEIN, HUMAN; NERVE GROWTH FACTOR; ONCOLYTIC VIRUS; SMALL INTERFERING RNA;

ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENETIC ENGINEERING AND GENE TECHNOLOGY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; TUMOR CELL; TUMOR GROWTH; VALIDATION PROCESS; VIRUS DETECTION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; WESTERN BLOTTING; ANIMAL; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG SCREENING; GENE SILENCING; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; NERVE SHEATH NEOPLASMS; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SURVIVAL; TUMOR CELL LINE; VALIDATION STUDY;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENETIC ENGINEERING; HERPESVIRUS 1, HUMAN; HUMANS; LUCIFERASES; MICE; MICE, NUDE; NERVE GROWTH FACTORS; NERVE SHEATH NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC; TRANSGENES; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

HUMAN HERPESVIRUS 1; MUS MUSCULUS; SIMPLEXVIRUS;

EID: 77955652027     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1479     Document Type: Article

References (60)

1. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008; 1785: 217-231.
2. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther 2005; 12: 585-598. (Pubitemid 41350140)
3. Kasuya H, Takeda S, Nomoto S, et al. The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther 2005; 12: 725-736. (Pubitemid 41208612)
4. Kemeny N, Brown K, Covey A, et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006; 17: 1214-1224.
5. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867-874.
6. Kelly KJ, Wong J, Fong Y. Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy. Expert Opin Investig Drugs 2008; 17: 1105-1113.
7. Fong Y, Kim T, Bhargava A, et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 2009; 17: 389-394.
8. Aghi MK, Chiocca EA. Phase Ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol Ther 2009; 17: 8-9.
9. Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009; 17: 199-207.
10. Otsuki A, Patel A, Kasai K, et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 2008; 16: 1546-1555.
11. Currier MA, Gillespie RA, Sawtell NM, et al. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther 2008; 16: 879-885.
12. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9: 967-978. (Pubitemid 35462560)
13. Fu X, Meng F, Tao L, et al. A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus. Gene Ther 2003; 10: 1458-1464. (Pubitemid 36987139)
14. Kuroda T, Rabkin SD, Martuza RL. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res 2006; 66: 10127-10135.
15. Horst M, Brouwer E, Verwijnen S, et al. Targeting malignant gliomas with a glial fibrillary acidic protein (GFAP)-selective oncolytic adenovirus. J Gene Med 2007; 9: 1071-1079. (Pubitemid 350286412)
16. Delgado-Enciso I, Cervantes-Garcia D, Martinez-Davila IA, et al. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms. J Gene Med 2007; 9: 852-861. (Pubitemid 47543252)
17. Bell JC. Oncolytic viruses: what's next? Current Cancer Drug Targets 2007; 7: 127-131.
18. Mahller YY, Williams JP, Baird WH, et al. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 2009; 4: e4235.
19. Cripe TP, Wang PY, Marcato P, et al. Targeting cancer-initiating cells with oncolytic viruses. Mol Ther 2009; 17: 1677-1682.
20. Tsutsui J, Kadomatsu K, Matsubara S, et al. A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res 1993; 53: 1281-1285.
21. Mashour GA, Ratner N, Khan GA, et al. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 2001; 20: 97-105. (Pubitemid 32142342)
22. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem (Tokyo) 2002; 132: 359-371.
23. Takei Y, Kadomatsu K, Itoh H, et al. 5′-, 3′-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy. J Biol Chem 2002; 277: 23800-23806.
24. Shimada H, Nabeya Y, Tagawa M, et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 2003; 94: 628-632. (Pubitemid 36975019)
25. Ikematsu S, Nakagawara A, Nakamura Y, et al. Plasma midkine level is a prognostic factor for human neuroblastoma. Cancer Sci 2008; 99: 2070-2074.
26. Ibusuki M, Fujimori H, Yamamoto Y, et al. Midkine in plasma as a novel breast cancer marker. Cancer Sci 2009; 100: 1735-1739.
27. Lucas S, Reindl T, Henze G, et al. Increased midkine serum levels in pediatric embryonal tumor patients. J Pediatr Hematol Oncol 2009; 31: 713-717.
28. Adachi Y, Reynolds PN, Yamamoto M, et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res 2001; 61: 7882-7888.
29. Adachi Y, Matsubara S, Muramatsu T, et al. Midkine promoter-based adenoviral suicide gene therapy to midkine-positive pediatric tumor. J Pediatr Surg 2002; 37: 588-592. (Pubitemid 34293097)
30. He B, Chou J, Brandimarti R, et al. Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 1997; 71: 6049-6054. (Pubitemid 27304944)
31. Ward SL, Scheuner D, Poppers J, et al. In vivo replication of an ICP34.5 second-site suppressor mutant following corneal infection correlates with in vitro regulation of eIF2 alpha phosphorylation. J Virol 2003; 77: 4626-4634.
32. Mulvey M, Poppers J, Sternberg D, et al. Regulationof eIF2alpha phosphorylation by different functions that act during discrete phases in the herpes simplex virus type 1 life cycle. J Virol 2003; 77: 10917-10928.
33. Harland J, Dunn P, Cameron E, et al. The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins. J Neurovirol 2003; 9: 477-488. (Pubitemid 36986814)
34. Chung RY, Saeki Y, Chiocca EA. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol 1999; 73: 7556-7564.
35. Mullen JT, Kasuya H, Yoon SS, et al. Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann Surg 2002; 236: 502-512.
36. Kambara H, Okano H, Chiocca EA, et al. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005; 65: 2832-2839.
37. Hardcastle J, Kurozumi K, Chiocca EA, et al. Oncolytic viruses driven by tumor-specific promoters. Current Cancer Drug Targets 2007; 7: 181-189.
38. Mahller YY, Rangwala F, Ratner N, et al. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Pediatr Blood Cancer 2006; 46: 745-754.
39. Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001; 61: 7388-7393.
40. Terada K, Wakimoto H, Tyminski E, et al. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther 2006; 13: 705.
41. Ravi V, Desai A, Madhusudana SN. Virology Manual of the Department Of Neurovirology, National Institute of Mental Health and Neuro Sciences (NIMHANS): Bangalore, India, 2004.
42. Randall RE, Newman C, Honess RW. Asynchronous expression of the immediate-early protein of herpesvirus saimiri in populations of productively infected cells. J Gen Virol 1985; 66: 2199-2213. (Pubitemid 15250299)
43. Liu TC, Zhang T, Fukuhara H, et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res 2006; 12: 6791-6799.
44. Liu TC, Zhang T, Fukuhara H, et al. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther 2006; 14: 789-797. (Pubitemid 44752718)
45. Messerli SM, Prabhakar S, Tang Y, et al. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther 2006; 17: 20-30.
46. Mahller YY, Vaikunth SS, Currier MA, et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther 2007; 15: 279-286.
47. Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, et al. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther 2007; 14: 460-467. (Pubitemid 46588196)
48. Mahller YY, Vaikunth SS, Ripberger MC, et al. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 2008; 68: 1170-1179.
49. Mahller YY, Sakthivel B, Baird WH, et al. Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication. Cancer Gene Ther 2008; 15: 733-741.
50. Farassati F, Pan W, Yamoutpour F, et al. Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am J Pathol 2008; 173: 1861-1872.
51. Watson MA, Perry A, Tihan T, et al. Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol 2004; 14: 297-303.
52. Leroy K, Dumas V, Martin-Garcia N, et al. Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. Arch Dermatol 2001; 137: 908-913. (Pubitemid 32641650)
53. Petrowsky H, Roberts GD, Kooby DA, et al. Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol 2001; 75: 7050-7058. (Pubitemid 32641592)
54. Bennett JJ, Adusumilli P, Petrowsky H, et al. Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J 2004; 18: 1001-1003.
55. Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 2006; 98: 38-50. (Pubitemid 43057091)
56. Thorley-Lawson DA, Allday MJ. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 2008; 6: 913-924.
57. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987; 47: 3039-3051.
58. Netti PA, Berk DA, Swartz MA, et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000; 60: 2497-2503.
59. McKee TD, Grandi P, Mok W, et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006; 66: 2509-2513.
60. Kaur B, Chiocca EA. Personalizing oncolytic virotherapy? Mol Ther 2007; 15: 6-7. (Pubitemid 46043641)